IVBM All Coverage

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.

In part 3 of this conversation, Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, discusses why basic scientific research remains essential and how patient experiences contribute.

Clayton Irvine, PharmD, MBA, MS, senior manager of oncology care at Mayo Clinic, emphasizes the need for health care providers to balance quality patient care with rising costs by openly discussing financial implications with patients and educating themselves on cost-effective treatments.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient and system costs by optimizing the use of generics and biosimilars, which offer lower costs without compromising safety and efficacy.

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common theme emerged: the need to balance innovation with patient-centered, equitable, and sustainable care models.

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.

In part 2 of our interview with Karen Winkfield, MD, PhD, she speaks to the importance of ensuring health care accessibility and of knowing that the health care system is not a one-size-fits-all arrangement.

In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.

Cochair of our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Oscar B. Lahoud, MD, speaks on his hoped-for top health care priorities under the incoming administration.

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.

In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.

Song Park, MD, University of Washington Medicine, advocates for more user-friendly technology to support equitable skin cancer care access.

In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.

Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.

The top content from the Institute for Value-Based Medicine® (IVBM®) highlighted innovative approaches to improving care delivery, addressing obesity, and tackling health inequities across various disciplines.

Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature.

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.

Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.

In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the increasing role of genomic profiling in tailoring treatment plans.

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Oncology pharmacists play a vital role in managing complex outpatient therapies by assessing patient suitability, educating patients, and implementing protocols to ensure safe and effective treatment.

At our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Brita Roy, MD, MPH, MHS, spoke on improving cancer health outcomes through community-clinical partnerships.